GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA

Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1

New hope for tough cancers: experimental drug targets advanced tumors

Disease control ENROLLING_BY_INVITATION

This early-stage study is testing a new drug called RNDO-564, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced cancers that have stopped responding to standard treatments. The main goals are to find safe doses and see how the bod…

Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA

Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control

Last updated Mar 27, 2026 12:37 UTC

GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA

Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear

New hope for tough cancers: experimental drug targets advanced tumors